Skip to content

Cost-effectiveness analysis of Xiangbi Decoction in the treatment of Cervical radiculopathy

Cost-effectiveness analysis of Xiangbi Decoction and Jingtong Granule in the Management of Cervical Radiculopathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018918
Enrollment
Unknown
Registered
2018-10-16
Start date
2018-10-15
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical radiculopathy

Interventions

Experimental group:Xiangbi Decoction (one bag at a time, 2 times a day, 2 weeks)
Control group:Jingtong Granule (one bag at a time,3 times a day, 2 weeks)

Sponsors

Wangjing Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Cervical pain accompanied by upper extremity radiation pain, cervical X-ray showed vertebral body hyperplasia, hook joint hyperplasia was obvious, intervertebral foramen of intervertebral space became smaller; 2. aged from 45 to 65 old years;

Exclusion criteria

Exclusion criteria: 1. cervical extra-vertebral lesions (such as thoracic hemorrhage syndrome, carpal tunnel syndrome, frozen shoulder); 2. Suspected or confirmed cervical vertebrae and intraspinal tumors, brain tumors; 3. Hematological patients with bleeding tendency; 4. bone and joint tuberculosis, osteomyelitis and senile osteoporosis; 5. the diagnosis of spinal cord injury with spinal cord injury symptoms; 6. developmental spinal stenosis (vertebral canal ratio = sagittal radial diameter / vertebral sagittal diameter <0.75); 7. Patients with severe heart, lung and brain diseases; 8. Those with severe skin damage or skin diseases in the manipulation area; 9. cervical spondylosis.

Design outcomes

Primary

MeasureTime frame
Pain visual analogue scale;Neck Disability Index;Cost-effectiveness ratio;Incremental cost effectiveness ratio;Sensitivity Analysis;

Countries

China

Contacts

Public ContactYu Chenchen

Wangjing Hospital, China Academy of Chinese Medical Sciences

kjcycc@163.com+86 13911710827

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026